$1.4 million FY08
TSC MEMBER INSTITUTION(S):
National Institutes of Health
ABOUT THE COMPANY:
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions.
Professor Yigong Shi, formerly of Princeton University’s Department of Molecular Biology, developed TetraLogic’s core technology, called Inhibitor of Apoptosis Proteins (IAP), which enables drugs to be developed that unblock the cell death or apoptosis pathway, resulting in the death of tumor cells.
The company’s Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
TetraLogic recently announced that it has completed a $36 million Series B private equity financing process. Proceeds from the financing will be invested to advance its Inhibitor of Apoptosis Proteins antagonist oncology program through initial clinical trials. TetraLogic has made substantial progress in its research and development efforts on the IAP antagonist.
UNIVERSITY-BASED RESEARCH CONNECTION:
One of TetraLogics’s founding scientists is Yigong Shi, formerly of Princeton University’s Department of Molecular Biology
ROLE OF FEDERAL RESEARCH FUNDING:
Professor Shi’s work was supported in part with funding from the National Institutes of Health.
Read The Full Report Here